For more than 100 years, insulin has been the foundation of treatment for Type 1 Diabetes.
While insulin remains essential, researchers have continued searching for ways to protect the body’s remaining insulin-producing cells and slow the progression of the disease.
One of the most exciting recent developments is a therapy called Tzield (teplizumab).
Understanding Type 1 Diabetes
Type 1 Diabetes occurs when the body’s immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
As these cells are gradually destroyed, the body loses its ability to produce enough insulin, making lifelong insulin therapy necessary.
What Makes Tzield Different?
Unlike insulin, which replaces what the body cannot produce, Tzield works by targeting the immune system itself.
The goal is to slow the autoimmune attack and preserve the body’s remaining insulin-producing cells.
Why Is This Important?
Preserving beta cell function may provide several benefits:
- Better blood sugar control
- Reduced insulin requirements
- Improved metabolic stability
- Better quality of life
Clinical studies have shown that individuals treated with Tzield experienced a slower decline in insulin production compared with those who did not receive the treatment.
A New Direction in Diabetes Care
For many years, diabetes treatment focused mainly on managing blood sugar levels.
Tzield represents a different approach—one that aims to modify the course of the disease itself.
Although it is not a cure, it marks an important step forward in Type 1 Diabetes care.
Looking to the Future
Advances in immunotherapy, genetics, and precision medicine continue to improve our understanding of Type 1 Diabetes.
Treatments like Tzield offer hope that future generations may experience better outcomes and improved quality of life.
Dr. Raj Diabetes Centre & Sugbee Team